 Shares of Momenta Pharmaceuticals NASDAQ:MNTA rose 1 after the company reported Q2 results.Quarterly Results Earnings per share increased 58.62 year over year to 0.48, which missed the estimate of 0.39.Revenue of 6,610,000 higher by 27.56 year over year, which beat the estimate of 5,560,000.Outlook Momenta Pharmaceuticals hasnt issued any earnings guidance for the time being.Momenta Pharmaceuticals hasnt issued any revenue guidance for the time being.Details Of The Call Date: Aug 10, 2020View more earnings on MNTATime: 08:30 AMET Webcast URL: Action Companys 52-week high was at 39.8852-week low: 11.29Price action over last quarter: Up 0.70Company Profile Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in genericsbiosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.See more from Benzinga Earnings Scheduled For August 10, 2020 Stocks That Hit 52-Week Highs On Tuesday Stocks That Hit 52-Week Highs On FridayC 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved. 